ECZEMA

This study tested whether a team-based online care model works as well as in-person visits for managing atopic dermatitis (eczema). 300 patients were randomly assigned to either online or in-person care for 12 months. Researchers measured changes in disease severity, quality of l…

This study tested whether a moisturizer containing postbiotics (beneficial yeast and bacteria) can lower the chance of eczema returning in children aged 0-6 years whose skin had cleared up. 98 children used either the special moisturizer or a regular one. The goal was to see if t…

This study tested a new medicine called camoteskimab in 62 adults with moderate to severe eczema (atopic dermatitis). The goal was to see if it reduces skin redness, itching, and rash better than a placebo over 12 weeks. Participants received either the drug or a placebo, and som…

This study tested an experimental drug called EVO301 in 71 adults with moderate-to-severe atopic dermatitis (eczema). The goal was to see if the drug is safe and can reduce the severity and extent of eczema compared to a placebo. Participants received either EVO301 or a dummy tre…

This study tested two creams—crisaborole and fluticasone—on 40 children aged 1 to 12 with mild to moderate eczema. Both creams were applied twice daily for 6 weeks, then twice weekly for 12 weeks if the skin improved a lot. Both treatments helped reduce itching and skin redness, …

This study looked at how dupilumab affects the immune cells and genes inside the skin of people with moderate-to-severe eczema. Seventeen adults took the drug and had skin samples tested before and after 12 weeks of treatment. The goal was to understand how the medicine works at …

This study looked at a specific immune pathway (PGE2/IL22/IL17) in people with eczema to understand how it contributes to the disease. Researchers measured levels of these immune signals in skin and blood samples from 38 participants, including those with eczema, psoriasis, and h…